Richard P Slaughter Associates Inc Has $2.70 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Richard P Slaughter Associates Inc lowered its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 25.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 111,494 shares of the biopharmaceutical company's stock after selling 37,912 shares during the quarter. Richard P Slaughter Associates Inc owned about 0.09% of Catalyst Pharmaceuticals worth $2,704,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $27,000. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $29,000. Farther Finance Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $65,000. Finally, KBC Group NV raised its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after buying an additional 1,542 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on CPRX. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Robert W. Baird raised their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday. Finally, Stephens reissued an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Six analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $32.83.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the transaction, the insider now owns 68,873 shares in the company, valued at $1,627,468.99. This trade represents a 38.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Trading Up 2.0%

Shares of CPRX traded up $0.51 during midday trading on Friday, reaching $25.87. 1,201,295 shares of the stock were exchanged, compared to its average volume of 1,115,822. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.75 and a 52 week high of $26.16. The company has a market capitalization of $3.16 billion, a P/E ratio of 21.92, a PEG ratio of 3.31 and a beta of 0.72. The company's 50 day moving average is $23.64 and its two-hundred day moving average is $22.75.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.